Telmisartan Versus Ramipril After Acute Coronary Syndrome
Phase 4
- Conditions
- Acute Coronary SyndromeMyocardial InfarctionCoronary Disease
- Interventions
- Registration Number
- NCT00702936
- Lead Sponsor
- Catholic University of the Sacred Heart
- Brief Summary
The purpose of this study is to compare the antinflammatory and endothelial progenitor cell (EPC) mobilizing effect of Ramipril and Telmisartan in patients presenting with acute coronary syndrome
- Detailed Description
Not available
Recruitment & Eligibility
- Status
- UNKNOWN
- Sex
- All
- Target Recruitment
- 50
Inclusion Criteria
- Biochemical evidence of myocardial infarction as indicated by elevation of cTnT,
- presence of ECG ischemic changes,
- angiographic evidence of a primary coronary event, such as plaque erosion and/or rupture, fissuring, or dissection at coronary angiography,
- successful coronary revascularization of at least one culprit coronary vessel.
Exclusion Criteria
- Age>80 years, current ACE inhibitor or ARB treatment,
- ejection fraction <35%, infarction secondary to ischemia due to an imbalance of O2 supply and demand,
- ECG abnormalities that could affect the recognition of ST segment shift,
- recent or chronic infective or inflammatory diseases,
- malignancy, and myocardial infarction,
- surgery or trauma in the previous month.
Study & Design
- Study Type
- INTERVENTIONAL
- Study Design
- PARALLEL
- Arm && Interventions
Group Intervention Description R RAMIPRIL Twenty-five patients assigned to ramipril 5 mg daily T TELMISARTAN Twenty-five patients assigned to Telmisartan 80 mg daily
- Primary Outcome Measures
Name Time Method High sensitivity C-Reactive Protein 20 days after hospital discharge
- Secondary Outcome Measures
Name Time Method Endothelial Progenitor Cells 20 days after hospital discharge
Trial Locations
- Locations (1)
Catholic University of the Sacred Heart
🇮🇹Rome, Italy